导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.40% | 2708/4773 |
| 近一周 | -1.72% | 3174/5467 |
| 近一月 | -5.27% | 2277/5421 |
| 近一季 | -7.67% | 2426/5238 |
| 近半年 | -1.71% | 2061/4931 |
| 近一年 | 0.47% | 2481/4400 |
| 近两年 | 42.86% | 1744/2954 |
| 近三年 | 24.73% | 1301/2253 |
| 成立以来 | 86.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.51% 3251/4961 |
12.04% 2247/5312 |
- - |
- - |
| 2025 | 18.45% 2315/4813 |
-1.27% 2621/3635 |
2.14% 1826/4076 |
17.39% 2512/4524 |
0.06% 2247/4813 |
| 2024 | 15.25% 946/3463 |
2.69% 728/2808 |
-1.27% 1017/3014 |
15.82% 1617/3129 |
-1.86% 1863/3463 |
| 2023 | -9.77% 1228/2656 |
4.22% 1014/2280 |
-3.60% 842/2385 |
-3.48% 941/2515 |
-6.96% 1993/2655 |
| 2022 | -18.95% 779/2207 |
-13.77% 832/1919 |
6.62% 649/2016 |
-13.31% 878/2113 |
1.69% 1178/2208 |
| 2021 | 0.07% 729/1822 |
-2.37% 632/1255 |
5.52% 804/1330 |
-4.50% 713/1466 |
1.72% 824/1822 |
| 2020 | 38.15% 366/1250 |
-8.49% 615/1028 |
14.98% 526/1067 |
14.73% 260/1164 |
14.44% 275/1184 |
| 2019 | - - |
- - |
-0.08% 207/788 |
2.21% 314/850 |
7.62% 419/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 鹏华沪深300ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |